{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:48:15Z","timestamp":1756385295997,"version":"3.37.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["BD\/128333\/2017","DL 57\/2016 \u2013 Norma Transit\u00f3ria","SFRH\/BPD\/98304\/2013","UIDB\/04378\/2020"],"award-info":[{"award-number":["BD\/128333\/2017","DL 57\/2016 \u2013 Norma Transit\u00f3ria","SFRH\/BPD\/98304\/2013","UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10549-021-06376-4","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T16:03:01Z","timestamp":1631116981000},"page":"227-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression"],"prefix":"10.1007","volume":"190","author":[{"given":"Tiago V.","family":"Augusto","sequence":"first","affiliation":[]},{"given":"Cristina","family":"Amaral","sequence":"additional","affiliation":[]},{"given":"Yuanzhong","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Shiuan","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Cristina F.","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Nat\u00e9rcia","family":"Teixeira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5787-9018","authenticated-orcid":false,"given":"Georgina","family":"Correia-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"issue":"1","key":"6376_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1020299707510","volume":"76","author":"WF Anderson","year":"2002","unstructured":"Anderson WF et al (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76(1):27\u201336","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"6376_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623\u20131649","journal-title":"Ann Oncol"},{"issue":"10","key":"6376_CR3","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F et al (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(10):1674","journal-title":"Ann Oncol"},{"issue":"5","key":"6376_CR4","doi-asserted-by":"publisher","first-page":"R283","DOI":"10.1530\/ERC-17-0425","volume":"25","author":"TV Augusto","year":"2018","unstructured":"Augusto TV et al (2018) Acquired resistance to aromatase inhibitors: where we stand! Endocr Relat Cancer 25(5):R283\u2013R301","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"6376_CR5","first-page":"2821","volume":"9","author":"B Rozeboom","year":"2019","unstructured":"Rozeboom B, Dey N, De P (2019) ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res 9(12):2821\u20132831","journal-title":"Am J Cancer Res"},{"issue":"6","key":"6376_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/07853890.2014.912836","volume":"46","author":"M Martini","year":"2014","unstructured":"Martini M et al (2014) PI3K\/AKT signaling pathway and cancer: an updated review. Ann Med 46(6):372\u2013383","journal-title":"Ann Med"},{"issue":"4","key":"6376_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","volume":"9","author":"AB Hanker","year":"2019","unstructured":"Hanker AB, Kaklamani V, Arteaga CL (2019) Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors. Cancer Discov 9(4):482\u2013491","journal-title":"Cancer Discov"},{"issue":"7418","key":"6376_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"CG Atlas","year":"2012","unstructured":"Atlas CG, N. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370","journal-title":"Nature"},{"issue":"Suppl 7","key":"6376_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s12864-016-2911-z","volume":"17","author":"G Jiang","year":"2016","unstructured":"Jiang G et al (2016) Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics 17(Suppl 7):525","journal-title":"BMC Genomics"},{"issue":"3","key":"6376_CR10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1073\/pnas.0408864102","volume":"102","author":"S Kang","year":"2005","unstructured":"Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102(3):802\u2013807","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"6376_CR11","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI41680","volume":"120","author":"TW Miller","year":"2010","unstructured":"Miller TW et al (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120(7):2406\u20132413","journal-title":"J Clin Invest"},{"issue":"1","key":"6376_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J et al (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18(1):26","journal-title":"Mol Cancer"},{"issue":"Suppl 10","key":"6376_CR13","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","volume":"30","author":"SE Nunnery","year":"2019","unstructured":"Nunnery SE, Mayer IA (2019) Management of toxicity to isoform alpha-specific PI3K inhibitors. Ann Oncol 30(Suppl 10):x21\u2013x26","journal-title":"Ann Oncol"},{"issue":"6","key":"6376_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","volume":"17","author":"IE Krop","year":"2016","unstructured":"Krop IE et al (2016) Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17(6):811\u2013821","journal-title":"Lancet Oncol"},{"issue":"7","key":"6376_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J et al (2017) Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(7):904\u2013916","journal-title":"Lancet Oncol"},{"issue":"20","key":"6376_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940","journal-title":"N Engl J Med"},{"issue":"1","key":"6376_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer IA et al (2017) A phase Ib study of Alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with Letrozole in ER+\/HER2\u2212 metastatic breast cancer. Clin Cancer Res 23(1):26\u201334","journal-title":"Clin Cancer Res"},{"issue":"12","key":"6376_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","volume":"21","author":"H Ellis","year":"2019","unstructured":"Ellis H, Ma CX (2019) PI3K inhibitors in breast cancer therapy. Curr Oncol Rep 21(12):110","journal-title":"Curr Oncol Rep"},{"key":"6376_CR19","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/jco.2014.32.15_suppl.2605","volume":"32","author":"PD Shah","year":"2014","unstructured":"Shah PD et al (2014) Phase I trial of daily PI3K\u03b1 inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). J Clin Oncol 32:2605\u20132605","journal-title":"J Clin Oncol"},{"issue":"15","key":"6376_CR20","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1042\/BCJ20160170","volume":"473","author":"JM Backer","year":"2016","unstructured":"Backer JM (2016) The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34. Biochem J 473(15):2251\u20132271","journal-title":"Biochem J"},{"key":"6376_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1146\/annurev-genet-102808-114910","volume":"43","author":"C He","year":"2009","unstructured":"He C, Klionsky DJ (2009) Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43:67\u201393","journal-title":"Annu Rev Genet"},{"key":"6376_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.biopha.2018.05.007","volume":"104","author":"S Saha","year":"2018","unstructured":"Saha S et al (2018) Autophagy in health and disease: A comprehensive review. Biomed Pharmacother 104:485\u2013495","journal-title":"Biomed Pharmacother"},{"key":"6376_CR23","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2019.13","author":"AB Flynn","year":"2019","unstructured":"Flynn AB, Schiemann WP (2019) Autophagy in breast cancer metastatic dormancy: Tumor suppressing or tumor promoting functions? J Cancer Metastasis Treat. https:\/\/doi.org\/10.20517\/2394-4722.2019.13","journal-title":"J Cancer Metastasis Treat"},{"issue":"8","key":"6376_CR24","doi-asserted-by":"publisher","first-page":"e42398","DOI":"10.1371\/journal.pone.0042398","volume":"7","author":"C Amaral","year":"2012","unstructured":"Amaral C et al (2012) Apoptosis and autophagy in breast cancer cells following exemestane treatment. PLoS ONE 7(8):e42398","journal-title":"PLoS ONE"},{"key":"6376_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jsbmb.2018.05.006","volume":"183","author":"C Amaral","year":"2018","unstructured":"Amaral C et al (2018) Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance. J Steroid Biochem Mol Biol 183:51\u201361","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"6376_CR26","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1124\/mol.114.091850","volume":"85","author":"A Thorburn","year":"2014","unstructured":"Thorburn A, Thamm DH, Gustafson DL (2014) Autophagy and cancer therapy. Mol Pharmacol 85(6):830\u2013838","journal-title":"Mol Pharmacol"},{"issue":"3","key":"6376_CR27","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1096\/fj.201700477R","volume":"32","author":"W Yang","year":"2018","unstructured":"Yang W et al (2018) Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. FASEB J 32(3):1222\u20131235","journal-title":"FASEB J"},{"issue":"6","key":"6376_CR28","first-page":"2066","volume":"12","author":"JX Liu","year":"2019","unstructured":"Liu JX, Yue W, Chen HY (2019) The correlation between autophagy and tamoxifen resistance in breast cancer. Int J Clin Exp Pathol 12(6):2066\u20132074","journal-title":"Int J Clin Exp Pathol"},{"issue":"6762","key":"6376_CR29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/45257","volume":"402","author":"XH Liang","year":"1999","unstructured":"Liang XH et al (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402(6762):672\u2013676","journal-title":"Nature"},{"issue":"6","key":"6376_CR30","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/cr.2012.44","volume":"22","author":"MY Wu","year":"2012","unstructured":"Wu MY et al (2012) Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor. Cell Res 22(6):1003\u20131021","journal-title":"Cell Res"},{"issue":"7","key":"6376_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.molonc.2016.04.001","volume":"10","author":"M Cordani","year":"2016","unstructured":"Cordani M et al (2016) Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Mol Oncol 10(7):1008\u20131029","journal-title":"Mol Oncol"},{"key":"6376_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12885-016-2490-z","volume":"16","author":"A Lui","year":"2016","unstructured":"Lui A et al (2016) Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. BMC Cancer 16:487","journal-title":"BMC Cancer"},{"key":"6376_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12885-016-2270-9","volume":"16","author":"T Ueno","year":"2016","unstructured":"Ueno T et al (2016) Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC Cancer 16:230","journal-title":"BMC Cancer"},{"issue":"6","key":"6376_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529","journal-title":"N Engl J Med"},{"issue":"12","key":"6376_CR35","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol 25(12):2357\u20132362","journal-title":"Ann Oncol"},{"issue":"2","key":"6376_CR36","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.clbc.2017.09.004","volume":"18","author":"T Safra","year":"2018","unstructured":"Safra T et al (2018) Everolimus plus letrozole for treatment of patients With HR+, HER2\u2212 advanced breast cancer progressing on endocrine therapy: an open-label. Phase II Trial Clin Breast Cancer 18(2):e197\u2013e203","journal-title":"Phase II Trial Clin Breast Cancer"},{"issue":"4","key":"6376_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ejca.2008.10.019","volume":"45","author":"PE Lonning","year":"2009","unstructured":"Lonning PE (2009) Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 45(4):527\u2013535","journal-title":"Eur J Cancer"},{"issue":"12","key":"6376_CR38","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/0008-5472.CAN-08-0303","volume":"68","author":"S Masri","year":"2008","unstructured":"Masri S et al (2008) Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 68(12):4910\u20134918","journal-title":"Cancer Res"},{"issue":"4\u20135","key":"6376_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jsbmb.2009.10.011","volume":"118","author":"S Masri","year":"2010","unstructured":"Masri S et al (2010) Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J Steroid Biochem Mol Biol 118(4\u20135):277\u2013282","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"6376_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/omi.2010.0097","volume":"15","author":"S Chen","year":"2011","unstructured":"Chen S (2011) An \u201comics\u201d approach to determine the mechanisms of acquired aromatase inhibitor resistance. OMICS 15(6):347\u2013352","journal-title":"OMICS"},{"issue":"1\u20135","key":"6376_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jsbmb.2007.05.020","volume":"106","author":"S Chen","year":"2007","unstructured":"Chen S et al (2007) New experimental models for aromatase inhibitor resistance. J Steroid Biochem Mol Biol 106(1\u20135):8\u201315","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"21","key":"6376_CR42","first-page":"6949","volume":"50","author":"DJ Zhou","year":"1990","unstructured":"Zhou DJ, Pompon D, Chen SA (1990) Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50(21):6949\u20136954","journal-title":"Cancer Res"},{"key":"6376_CR43","doi-asserted-by":"crossref","unstructured":"Sun, X.Z., D. Zhou, and S. Chen, (1997) Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol. 63(1\u20133): 29\u201336.","DOI":"10.1016\/S0960-0760(97)00068-X"},{"issue":"19","key":"6376_CR44","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-13-0884","volume":"19","author":"JA Beaver","year":"2013","unstructured":"Beaver JA et al (2013) PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res 19(19):5413\u20135422","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6376_CR45","doi-asserted-by":"publisher","first-page":"R609","DOI":"10.1186\/bcr1262","volume":"7","author":"G Wu","year":"2005","unstructured":"Wu G et al (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7(5):R609\u2013R616","journal-title":"Breast Cancer Res"},{"key":"6376_CR46","doi-asserted-by":"publisher","first-page":"105486","DOI":"10.1016\/j.jsbmb.2019.105486","volume":"195","author":"TV Augusto","year":"2019","unstructured":"Augusto TV et al (2019) Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors. J Steroid Biochem Mol Biol 195:105486","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"6376_CR47","doi-asserted-by":"publisher","first-page":"165661","DOI":"10.1016\/j.bbadis.2019.165661","volume":"1866","author":"C Amaral","year":"2020","unstructured":"Amaral C et al (2020) The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane. Biochim Biophys Acta Mol Basis Dis 1866(5):165661","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"6376_CR48","doi-asserted-by":"crossref","unstructured":"Fraiberg, M. and Z. Elazar, Chapter Thirteen - Genetic defects of autophagy linked to disease, in Progress in Molecular Biology and Translational Science, A.B. Martinez and L. Galluzzi, Editors. 2020, Academic Press. p. 293\u2013323.","DOI":"10.1016\/bs.pmbts.2020.04.001"},{"issue":"4","key":"6376_CR49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.bbrc.2005.08.256","volume":"336","author":"YR Lee","year":"2005","unstructured":"Lee YR et al (2005) Up-regulation of PI3K\/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem Biophys Res Commun 336(4):1221\u20131226","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"6376_CR50","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1210\/me.2002-0330","volume":"17","author":"GE Stoica","year":"2003","unstructured":"Stoica GE et al (2003) Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17(5):818\u2013830","journal-title":"Mol Endocrinol"},{"issue":"6803","key":"6376_CR51","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/35035131","volume":"407","author":"T Simoncini","year":"2000","unstructured":"Simoncini T et al (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407(6803):538\u2013541","journal-title":"Nature"},{"issue":"4","key":"6376_CR52","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","volume":"1","author":"TW Miller","year":"2011","unstructured":"Miller TW et al (2011) ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338\u2013351","journal-title":"Cancer Discov"},{"issue":"13","key":"6376_CR53","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1074\/jbc.M010840200","volume":"276","author":"RA Campbell","year":"2001","unstructured":"Campbell RA et al (2001) Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(13):9817\u20139824","journal-title":"J Biol Chem"},{"key":"6376_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fonc.2012.00145","volume":"2","author":"EM Fox","year":"2012","unstructured":"Fox EM, Arteaga CL, Miller TW (2012) Abrogating endocrine resistance by targeting ERalpha and PI3K in breast cancer. Front Oncol 2:145","journal-title":"Front Oncol"},{"issue":"1","key":"6376_CR55","doi-asserted-by":"publisher","first-page":"9842","DOI":"10.1038\/s41598-017-10555-z","volume":"7","author":"IC Chen","year":"2017","unstructured":"Chen IC et al (2017) Phosphatidylinositol-3 kinase inhibitors, buparlisib and alpelisib, sensitize estrogen receptor-positive breast cancer cells to tamoxifen. Sci Rep 7(1):9842","journal-title":"Sci Rep"},{"issue":"1","key":"6376_CR56","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1038\/s41598-019-43429-7","volume":"9","author":"Y Yuan","year":"2019","unstructured":"Yuan Y et al (2019) Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. Sci Rep 9(1):7509","journal-title":"Sci Rep"},{"key":"6376_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2018.09.030","volume":"440\u2013441","author":"J Ding","year":"2019","unstructured":"Ding J et al (2019) Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K\u03b1 inhibition through the transcriptional regulation of ER\u03b1. Cancer Lett 440\u2013441:54\u201363","journal-title":"Cancer Lett"},{"issue":"8","key":"6376_CR58","doi-asserted-by":"publisher","first-page":"E1500","DOI":"10.1073\/pnas.1612991114","volume":"114","author":"Y Wang","year":"2017","unstructured":"Wang Y et al (2017) SGK3 sustains ER\u03b1 signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis. Proc Natl Acad Sci 114(8):E1500\u2013E1508","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"6376_CR59","doi-asserted-by":"publisher","first-page":"e0150564","DOI":"10.1371\/journal.pone.0150564","volume":"11","author":"MA Becker","year":"2016","unstructured":"Becker MA et al (2016) Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. PLoS ONE 11(3):e0150564","journal-title":"PLoS ONE"},{"issue":"33","key":"6376_CR60","doi-asserted-by":"publisher","first-page":"30458","DOI":"10.1074\/jbc.M305226200","volume":"278","author":"LA Martin","year":"2003","unstructured":"Martin LA et al (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278(33):30458\u201330468","journal-title":"J Biol Chem"},{"issue":"2","key":"6376_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41588-018-0287-5","volume":"51","author":"U Nayar","year":"2019","unstructured":"Nayar U et al (2019) Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet 51(2):207\u2013216","journal-title":"Nat Genet"},{"issue":"7","key":"6376_CR62","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1158\/0008-5472.CAN-07-5544","volume":"68","author":"X Wang","year":"2008","unstructured":"Wang X et al (2008) The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res 68(7):2259\u20132265","journal-title":"Cancer Res"},{"issue":"2","key":"6376_CR63","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/jcp.20395","volume":"205","author":"SR Lee","year":"2005","unstructured":"Lee SR et al (2005) Akt-induced promotion of cell-cycle progression at G2\/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol 205(2):270\u2013277","journal-title":"J Cell Physiol"},{"issue":"22","key":"6376_CR64","doi-asserted-by":"publisher","first-page":"7831","DOI":"10.1128\/MCB.22.22.7831-7841.2002","volume":"22","author":"ES Kandel","year":"2002","unstructured":"Kandel ES et al (2002) Activation of Akt\/protein kinase B overcomes a G(2)\/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22(22):7831\u20137841","journal-title":"Mol Cell Biol"},{"key":"6376_CR65","unstructured":"DiPaola, R.S., To Arrest or Not To G<sub>2<\/sub>-M Cell-Cycle Arrest. <span class=\"subtitle\">Commentary re: A. K. Tyagi <strong><em>et al.,<\/em><\/strong> Silibinin Strongly Synergizes Human Prostate Carcinoma DU145 Cells to Doxorubicin-induced Growth Inhibition, G<sub>2<\/sub>-M Arrest, and Apoptosis. Clin. Cancer Res., <strong><em>8:<\/em><\/strong> 3512\u20133519, 2002.<\/span>, 2002. 8(11): p. 3311\u20133314."},{"key":"6376_CR66","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12943-015-0480-4","volume":"14","author":"X Yu","year":"2015","unstructured":"Yu X et al (2015) MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol Cancer 14:208","journal-title":"Mol Cancer"},{"issue":"9","key":"6376_CR67","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1096\/fj.13-247353","volume":"28","author":"KL Cook","year":"2014","unstructured":"Cook KL et al (2014) Knockdown of estrogen receptor-\u03b1 induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death. Faseb j 28(9):3891\u20133905","journal-title":"Faseb j"},{"key":"6376_CR68","doi-asserted-by":"publisher","first-page":"23727","DOI":"10.1038\/srep23727","volume":"6","author":"P Totta","year":"2016","unstructured":"Totta P et al (2016) Dynamin II is required for 17\u03b2-estradiol signaling and autophagy-based ER\u03b1 degradation. Sci Rep 6:23727","journal-title":"Sci Rep"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06376-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06376-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06376-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T06:04:13Z","timestamp":1635660253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06376-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6376"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06376-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"AII the persons that contributed to this work are considered as authors and approved the final version of the manuscript. The Author transfers to Springer the non-exclusive publication rights and he warrants that his\/her contribution is original and that he\/she has full power to make this grant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}